Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | CASP1 | P29466 | 3/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6250862 | 0.91 | HSD17B10 (0.55) | HSD17B10ALDH1A1HPGDMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL6253886 | 0.86 | HSD17B10 (0.47) | HSD17B10ALDH1A1HPGDMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL6251457 | 0.84 | HSD17B10 (0.48) | HSD17B10ALDH1A1HPGDMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL6255163 | 0.82 | KDM4E (0.49) | HSD17B10ALDH1A1HPGDMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL6254265 | 0.81 | KDM4E (0.49) | HSD17B10ALDH1A1HPGDMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL6254195 | 0.80 | ADORA1 (0.50) | HSD17B10ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL6255229 | 0.75 | HSD17B10 (0.55) | HSD17B10ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL6252971 | 0.75 | HSD17B10 (0.45) | HSD17B10ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL6250193 | 0.74 | HSD17B10 (0.56) | HSD17B10ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL6254268 | 0.74 | EGFR (0.51) | HSD17B10ALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569645-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1569932-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040142978-A1 | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | US | disclosed |
| WO-2004055015-A1 | AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054505-A2 | METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127519-A1 | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP2K2, MAP3K2 | HSD17B10 3712/4885ALDH1A1 4315/4885HPGD 1207/4885 |
| US-20040142978-A1 | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 | MAP4K2, MAP3K20, MAPKAPK2 | HSD17B10 3911/4885ALDH1A1 3796/4885HPGD 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.